UK biotech financing April – June 2026
UK biotech financing reached a five-year high in Q2 2026, with total equity financing of £2.11 billion, including a record £2.05 billion in venture capital. Combined with the positive momentum seen in Q1, the first half of 2026 has delivered private investment at all levels, from start-ups to unicorns, plus a billion-dollar M&A, signalling a sustained recovery in fundraising and recyclable returns for both private and public sector investors.
The UK also reinforced its position as Europe’s leading biotech investment destination, accounting for 61% of Europe’s £3.3 billion venture capital placements during the quarter.
While the UK’s impressive headline was driven by Isomorphic Labs’ landmark £1.6 billion Series B, the underlying market recovery remains real. Excluding this landmark deal, UK biotech companies secured £498 million in venture capital during Q2, substantially outperforming the £279 million raised in Q2 2025. The fact that this sum included eight seed deals, averaging £6.4 million, with Series A and B+ each raising approximately £190 million and £225 million respectively shows investor appetite starting to cautiously extend across multiple stages of company growth.
Public markets, however, continue to trail private financing, showing relatively modest signs of improvement. Follow-on financing reached £58 million in Q2 2026 up from £36 million in Q1, and almost four times the £15 million raised in Q2 2025. Also, despite more positive signals before the conflicts in the Middle East, no UK biotech IPOs have been filed or launched so far in 2026.
